Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term follow-up of FCN-159 tablets in pediatric NF1 from FCN-159-002
CTR20251956Phase 2Active
- Sponsor
- Fosun Pharma
- Start
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of luvometinib in neurofibromatosis type 1 (NF1), sponsored by Fosun Pharma. Started Jun 2025; status: active.
02
Drugs
luvometinib
03
Conditions
neurofibromatosis type 1 (NF1)
Beyond the preview
Go deeper on CTR20251956.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20251956.